Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: Results of a multicentric phase II trial

1995 ◽  
Vol 33 (3) ◽  
pp. 265-268 ◽  
Author(s):  
Domenico Amoroso ◽  
Francesco Boccardo ◽  
Monica Balestrero ◽  
Loredana Miglietta ◽  
Fulvio Brema ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Breast ◽  
Megestrol Acetate ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer

1990 ◽  
Vol 27 (1) ◽  
pp. 79-80
Author(s):  
Mary E R O'Brien ◽  
E J Bayliss ◽  
Moira E Stewart ◽  
John F Smyth ◽  
Alan Rodger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Phase II Trial of 5-Fluorouracil and High-Dose Folinic Acid as First- or Second-Line Therapy for Advanced Breast Cancer

1994 ◽  
Vol 17 (2) ◽  
pp. 175-180 ◽  
Author(s):  
Kim A. Margolin ◽  
Stephanie Green ◽  
Kent Osborne ◽  
James H. Doroshow ◽  
Steven A. Akman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Folinic Acid ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Breast ◽  
High Dose ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

1995 ◽  
Vol 13 (11) ◽  
pp. 2722-2730 ◽  
Author(s):  
B L Weber ◽  
C Vogel ◽  
S Jones ◽  
H Harvey ◽  
L Hutchins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Objective Response ◽  
Advanced Breast ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
Line Therapy

PURPOSE We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. PATIENTS AND METHODS A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. RESULTS The objective response rate for all patients was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line patients and 32% (95% CI, 20% to 47%) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second-line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. CONCLUSION Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.

MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer

2021 ◽  
pp. clincanres.4685.2020
Author(s):  
Patrick Neven ◽  
Stephen R.D. Johnston ◽  
Masakazu Toi ◽  
Joohyuk Sohn ◽  
Kenichi Inoue ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Subgroup Analysis ◽  
Advanced Breast ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document